ASPR pauses U.S. distribution of bamlanivimab and etesevimab due to variants

Jun 25, 2021 - 03:10 PM
COVID19 Web Sized

U.S. health care providers may no longer order the monoclonal antibodies bamlanivimab and etesevimab until further notice due to rising prevalence of the SARS-CoV-2 P.1 and B.1.351 variants, which are not susceptible to the combination therapy, the Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response announced today.

The Food and Drug Administration recommends providers use the alternative monoclonal antibody therapies REGEN-COV or sotrovimab, which are likely to remain active against these variants, ASPR said. Providers should use data on variants in their region and variant resistance information in the fact sheets for each authorized monoclonal antibody therapy to guide treatment decisions, ASPR said. 

ASPR and FDA plan to provide updates as new information becomes available. Stakeholders also may refer questions to COVID19Therapeutics@hhs.gov. 
 

Related News Articles

Headline
CDC releases 2025-26 respiratory disease season outlook
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…
Headline
OSHA extends comment period on proposal removing remaining COVID-19 emergency temporary standard requirements
The Occupational Safety and Health Administration today announced a 60-day extension of the comment period on its proposed rule to remove the remaining…
Headline
CDC says COVID-19 cases growing or likely growing in 45 states 
COVID-19 infections are growing or likely growing in 45 states and not changing in five states, according to the latest data from the Centers for Disease…
Headline
FDA announces recall of cefazolin by Sandoz for mislabeling
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
COVID-19 vaccination approved for older adults and high-risk, younger children
 The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
OSHA proposes removing remaining requirements of its COVID-19 emergency temporary standard
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…